Sponsors of oral Factor Xa anticoagulants may breathe a sigh of relief with news of the US FDA's acceptance of Portola Pharmaceuticals Inc.'s revised application for the accelerated approval of AndexXa (andexanet alfa) antidote.
Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way
FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.
More from Cardiovascular
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.